AstraZeneca enters agreement with Recordati for Seloken in Europe

AstraZeneca announced today that it has entered into an agreement with Recordati S.p.A (Recordati) for the commercial rights to Seloken/Seloken ZOK (metoprolol tartrate and metoprolol succinate respectively) and associated Logimax fixed-dose combination (metoprolol succinate and felodipine) treatments in Europe.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news